Skip to main content

Advertisement

Log in

Does the Presence of Anti-CCP Autoantibodies and Their Serum Levels Influence the Severity and Activity in Rheumatoid Arthritis Patients?

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

This study aims to investigate the association of the presence and of the titer of autoantibodies against cyclic citrullinated peptides (aCCP), with clinical manifestations and disease activity in a cohort of patients with rheumatoid arthritis (RA). From January 2000 through December 2005, 135 patients were diagnosed with RA at the Rheumatology Unit of our hospital. Demographic, clinical, laboratory, and therapeutic parameters were evaluated in all patients at study entry and at every follow-up visit. Positivity in aCCP and also their levels were determined for all patients. At the end of the study, we reevaluated the above parameters, dividing patients into aCCP positive and aCCP negative. From 135 patients, 53.3% were aCCP positive. The majority of aCCP-positive patients were males (p < 0.001), positive to rheumatoid factor (p < 0.001) and current smokers (p < 0.05). At diagnosis, aCCP-positive patients presented with higher tender joint counts (p < 0.001) and swollen joint counts (p < 0.001), and exhibited more active disease, expressed by higher disease activity scores for 28 joints (DAS-28) (p < 0.001). At the end of the study, aCCP-positive patients also displayed more active disease, with higher DAS-28 (p < 0.001), and more severe disease, as this was indicated by the higher radiological Larsen score (p < 0.001). The serum levels of aCCP were not found to be associated with disease activity and severity. In early RA, the presence of aCCP is associated with increased disease activity and severity. This was found to be independent of circulating levels of aCCP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hochberg MC, Spector TD (1990) Epidemiology of Rheumatoid Arthritis. Update. Epidemiol Rev 12:247–252

    PubMed  CAS  Google Scholar 

  2. Hochberg MC (1994) Predicting the prognosis of patients with rheumatoid arthritis. Is there a crystal ball? J Rheumatol 20:1265–1267

    Google Scholar 

  3. Turesson C, O’Fallon MW, Crowson CS, Gabriel SE, Matteson EL (2002) Occurrence of extra-articular disease manifestation is associated with excess mortality in a community-based cohort of patients with rheumatoid arthritis. J Rheumatol 29:62–67

    PubMed  Google Scholar 

  4. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  5. Quinn MA, Green MS, Emery P (1997) Evaluation and management of early inflammatory arthritis severity. Ann Rheum Dis 56:463–469

    Article  Google Scholar 

  6. Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anticyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65:845–851

    Article  PubMed  CAS  Google Scholar 

  7. Zendman AJW, van Venrooij WJ, Pruijn GJM (2006) Use and significance of anti-CCP autoantibodies in rheumatoid arhritis. Rheumatology 45:20–25

    Article  PubMed  CAS  Google Scholar 

  8. Ates A, Karaaslan Y, Aksaray S (2006) Predictive value of autoantibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 25:743–745

    Article  Google Scholar 

  9. Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 18:481–491

    CAS  Google Scholar 

  10. Davis MG, Dawes PT, Fowler PD et al (1990) Comparison and evaluation of a disease activity index for use in patients with rheumatoid arthritis. Br J Rheumatol 29:111–115

    Article  PubMed  CAS  Google Scholar 

  11. Von Schaardenbourg D, Hazes IMW, de Boer A (1993) Outcome of rheumatoid arthritis relation to age and rheumatoid factors at diagnosis. J Rheumatol 20:45–52

    Google Scholar 

  12. Houssien DA, Jonsson T, Davies E, Scott D (1998) Rheumatoid factors isotypes, disease activity and the outcome of rheumatoid arthritis. Scand J Rheumatol 27:46–53

    Article  PubMed  CAS  Google Scholar 

  13. Mattey DL, Dawes PT, Clarke S et al (2002) Relationship among the HLA-DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis. Arthritis Rheum 47:403–407

    Article  PubMed  CAS  Google Scholar 

  14. De Rycke L, Peene I, Hoffman IG et al (2004) Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 63:1587–1593

    Article  PubMed  CAS  Google Scholar 

  15. Herold M, Boeser V, Russe E, Klotz W (2005) Anti-CCP: history and its usefulness. Clin Dev Immunol 12:131–135

    Article  PubMed  CAS  Google Scholar 

  16. Lee W, Weisman MH (2006) The predictive power of anti-cyclic citrullinated peptide antibodies: window into understanding gene/environment/immunity intractions. J Rheumatol 33:1216–1217

    PubMed  Google Scholar 

  17. Russell AS, Devani A, Maksymowych WP (2006) The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 33:1240–1242

    PubMed  CAS  Google Scholar 

  18. Kaltenhauser S, Pierer M, Arnold S, Kamprad M, Baerwald C, Hantzschel, H, Wagner U (2007) Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rheumatology (Oxford) 46:100–104

    Article  CAS  Google Scholar 

  19. Nell VP, Machold KP, Stamm TA et al (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736

    Article  PubMed  CAS  Google Scholar 

  20. Skogh T (2005) Does positive anti-CCP test identify a distinct arthritis entity? Arthritis Res Ther 7:R230–232

    Article  CAS  Google Scholar 

  21. van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7:R949–R958

    Article  PubMed  CAS  Google Scholar 

  22. Samanci N, Ozdem S, Akbas H, Mutlu D, Gultekin M, Arman M, Donmez, L (2005) Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis. J Natl Med Assoc 97:1120–1126

    PubMed  Google Scholar 

  23. Quinn MA, Gough AK, Green MJ, Devlin J, Greenstein A, Fraser A, Emery P (2006) Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 45:478–480

    Article  CAS  Google Scholar 

  24. Mewar D, Coote A, Moore DJ, Marinou L, Dickson MC, Montgomery DS, Binks MH, Wilson AG (2006) Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 8:R128

    Article  PubMed  CAS  Google Scholar 

  25. Korkmaz C, Us T, Kasifoglou T, Akgun Y (2006) Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem 39:961–965

    Article  PubMed  CAS  Google Scholar 

  26. Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: associaton with severity of disease in established RA. Clin Rheumatol 26:201–204

    Article  PubMed  Google Scholar 

  27. Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Ronnelid, J (2007) Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66:59–64

    Article  PubMed  CAS  Google Scholar 

  28. Aotsuka S, Okawa-Takatsuji M, Nagatani K, Nagashio C, Kano T, Nakajima K, Ito K, Mimori A (2005) A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. Clin Exp Rheumatol 23:475–481

    PubMed  CAS  Google Scholar 

  29. Del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Loza Cortina E (2006) Anticyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 24:281–286

    PubMed  CAS  Google Scholar 

  30. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapaa-Dahlqvist S (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann Rheum Dis 65:453–458

    Article  PubMed  CAS  Google Scholar 

  31. Greiner A, Plischke H, Kellner H, Gruber R (2005) Association of anti-cyclic citrullinated peptide antibodies, anti-citrulline antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 1050:295–303

    Article  PubMed  CAS  Google Scholar 

  32. Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, Wong K, Centola M, El-Gabalawy HS (2004) A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide in patients with early untreated inflammatory arthritis. J Rheumatol 31:2336–2346

    PubMed  CAS  Google Scholar 

  33. Albano S, Santana-Sahagun E, Weisman MH (2001) Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 31:146–159

    Article  PubMed  CAS  Google Scholar 

  34. Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos AA (2005) Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 23:861–866

    PubMed  CAS  Google Scholar 

  35. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Ccessie S, Breedveld FC, Toes RE, Huizinga TW (2006) Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65:366–371

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nikolaos G. Papadopoulos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papadopoulos, N.G., Tsiaousis, G.Z., Pavlitou-Tsiontsi, A. et al. Does the Presence of Anti-CCP Autoantibodies and Their Serum Levels Influence the Severity and Activity in Rheumatoid Arthritis Patients?. Clinic Rev Allerg Immunol 34, 11–15 (2008). https://doi.org/10.1007/s12016-007-8018-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-007-8018-1

Keywords

Navigation